Orthocell Limited (ASX:OCC) Submits FDA Application for Remplir™
Orthocell submits its FDA application for Remplir™, targeting the US nerve repair market, with clearance expected by April 2025.
Orthocell submits its FDA application for Remplir™, targeting the US nerve repair market, with clearance expected by April 2025.
Imugene Limited (ASX:IMU) secures $11 million R&D tax refund to advance its immuno-oncology therapies.
EBR Systems, Inc. announces a scheduled FDA Pre-Approval Inspection for its wireless cardiac pacing device, a pivotal step in regulatory progress.
Clarity Pharmaceuticals (ASX:CU6) unveils a novel radiopharmaceutical, SAR-bisFAP, enhancing cancer diagnosis and treatment potential.
Carbonxt Group Limited (ASX:CG1) has achieved mechanical completion of its Kentucky plant, enhancing its capacity to meet activated carbon market demand.
Adisyn Ltd has completed due diligence for acquiring 2D Generation, enhancing its semiconductor technology capabilities for the generative AI market.
MetalsTech Limited (ASX:MTC) provides updates on the Sturec Gold Mine’s operations, maintenance, and identified mineralisation potential.
MONEYME secures a strategic A$125 million funding facility with iPartners, enhancing growth and refinancing existing debt.
Triangle Energy (ASX:TEG) reports the first payment for the Cliff Head project sale remains unpaid, creating immediate financial implications.
Skin Elements Limited (ASX:SKN) has requested a trading halt pending significant announcements regarding a court application and capital raising.